Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Up - What's Next?

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) gapped up before the market opened on Tuesday . The stock had previously closed at $16.25, but opened at $17.15. Teva Pharmaceutical Industries shares last traded at $16.96, with a volume of 3,659,756 shares traded.

Analyst Ratings Changes

TEVA has been the subject of a number of recent research reports. Piper Sandler lifted their price target on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an "overweight" rating in a research note on Friday, January 17th. Barclays lowered their target price on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. StockNews.com downgraded Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Finally, UBS Group cut their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a research report on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $23.57.

Teva Pharmaceutical Industries Stock Performance

The stock's 50 day moving average is $19.93 and its two-hundred day moving average is $18.50. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The stock has a market cap of $18.97 billion, a price-to-earnings ratio of -11.55, a PEG ratio of 1.44 and a beta of 0.71.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Analysts anticipate that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the transaction, the director now directly owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This represents a 29.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.55% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of TEVA. Oarsman Capital Inc. acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $29,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at $44,000. Smithfield Trust Co increased its position in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after buying an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Finally, Venturi Wealth Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth about $60,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.